Artemisinin reduces the level of antibodies to gliadin in schizophrenia

Schizophrenia Research

Volumn 129, Issue 2-3, 2011, Pages 196-200

  Dickerson, Faith ^a   Stallings, Cassie ^a   Vaughan, Crystal ^a   Origoni, Andrea ^a   Goga, Joshana ^a   Khushalani, Sunil ^a   Yolken, Robert ^b  

^a Sheppard Pratt   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Artemisinin; Gliadin antibodies; Schizophrenia; Toxoplasma

Indexed keywords

ARIPIPRAZOLE; ARTEMISININ; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; GLIADIN ANTIBODY; HALOPERIDOL; OLANZAPINE; PLACEBO; PROTOZOON ANTIBODY; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARM FRACTURE; ARTICLE; COGNITION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOOT PAIN; FRACTURE; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; OUTPATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STARUS; RESPIRATORY TRACT DISEASE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM; THORAX PAIN; TOXOPLASMA GONDII; TREATMENT DURATION; UPPER RESPIRATORY ILLNESS;

ADULT; ANTI-INFECTIVE AGENTS; ANTIBODIES; ARTEMISININS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLIADIN; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 79957992692     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.04.010     Document Type: Article

References (28)

1. Anquetin G., Greiner J., Vierling P. Quinolone-based drugs against Toxoplasma gondii and Plasmodium spp. Curr. Drug Targets Infect. Disord. 2005, 5(3):227-245.
2. Arav-Boger R., He R., Chiou C.J., Liu J., Woodard L., Rosenthal A., Jones-Brando L., Forman M., Posner G. Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers. PLoS One 2010, 5(4):e10370.
3. Bereswill S., Muñoz M., Fischer A., Plickert R., Haag L.M., Otto B., Kühl A.A., Loddenkemper C., Göbel U.B., Heimesaat M.M. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One 2010, 5(12):e15099.
4. http://www.cfsan.fda.gov/~dms/supplmnt.html.
5. Chaudhary K., Ting L.M., Kim K., Roos D.S. Toxoplasma gondii purine nucleoside phosphorylase biochemical characterization, inhibitor profiles, and comparison with the Plasmodium falciparum ortholog. J. Biol. Chem. 2006, 281(35):25652-25658.
6. Debierre-Grockiego F. Glycolipids are potential targets for protozoan parasite diseases. Trends Parasitol. 2010, 26(8):404-411.
7. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Leister F., Yang S., Krivogorsky B., Alaedini A., Yolken R. Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia. Biol. Psychiatry 2010, 68(1):100-104.
8. Efferth T., Romero M.R., Wolf D.G., Stamminger T., Marin J.J., Marschall M. The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis. 2008, 47(6):804-811.
9. Fernandes G.C., Azevedo R.S., Amaku M., Yu A.L., Massad E. Seroepidemiology of Toxoplasma infection in a metropolitan region of Brazil. Epidemiol. Infect. 2009, 137(12):1809-1815.
10. Gopalakrishnan A.M., López-Estraño C. Comparative analysis of stage specific gene regulation of apicomplexan parasites: Plasmodium falciparum and Toxoplasma gondii. Infect. Disord. Drug Targets 2010, 10(4):303-311.
11. Gordi T., Lepist E.I. Artemisinin derivatives: toxic for laboratory animals, safe for humans?. Toxicol. Lett. 2004, 147(2):99-107.
12. http://holleypharma.com/.
13. Jones-Brando L., Torrey E.F., Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr. Res. 2003, 62(3):237-244.
14. Jones-Brando L., D'Angelo J., Posner G.H., Yolken R. In vitro inhibition of Toxoplasma gondii by four new derivatives of artemisinin. Antimicrob. Agents Chemother. 2006, 50(12):4206-4208.
15. Lehman A.F., Kreyenbuhl J., Buchanan R.W., Dickerson F.B., Dixon L.B., Goldberg R., Green-Paden L.D., Tenhula W.N., Boerescu D., Tek C., Sandson N., Steinwachs D.M. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr. Bull. 2004, 30(2):193-217.
16. Mausbach B.T., Harvey P.D., Goldman S.R., Jeste D.V., Patterson T.L. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr. Bull. 2007, 33(6):1364-1372.
17. Milbradt J., Auerochs S., Korn K., Marschall M. Sensitivity of human herpesvirus 6 and other human herpesviruses to the broad-spectrum antiinfective drug artesunate. J. Clin. Virol. 2009, 46(1):24-28.
18. Mortensen P.B., Norgaard-Pedersen B., Waltoft B.L., Sorensen T.L., Hougaard D., Yolken R.H. Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophr. Bull. 2007, 33(3):741.
19. Patterson T.L., Goldman S., McKibbin C.L., Hughs T., Jeste D.V. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr. Bull. 2001, 27(2):235-245.
20. Randolph, C., 1998. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The Psychological Corporation (Harcourt), San Antonio, TX.
21. Samaroo D., Dickerson F., Kasarda D.D., Green P.H., Briani C., Yolken R.H., Alaedini A. Novel immune response to gluten in individuals with schizophrenia. Schizophr. Res. 2010, 118(1-3):248-255.
22. Tawfik A.F., Bishop S.J., Ayalp A., el-Feraly, F.S. Effects of artemisinin, dihydroartemisinin and arteether on immune responses of normal mice. Int. J. Immunopharmacol. 1990, 12(4):385.
23. Torrey E.F., Bartko J.J., Lun Z.R., Yolken R.H. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2007, 33(3):729-736.
24. van Agtmael M.A., Eggelte T.A., van Boxtel C.J. Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol. Sci. 1999, 20(5):199-205.
25. Yolken R. Viruses and schizophrenia: a focus on herpes simplex virus. Herpes 2004, 11(Suppl 2):83A-88A.
26. Yolken R.H., Karlsson H., Yee F., Johnston-Wilson N.L., Torrey E.F. Endogenous retroviruses and schizophrenia. Brain Res. Rev. 2000, 31(2-3):193-199.
27. Yolken R.H., Bachmann S., Ruslanova I., Lillehoj E., Ford G., Torrey E.F., Schroeder J. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin. Infect. Dis. 2001, 32(5):842-844.
28. Zhao M., Xue D.B., Zheng B., Zhang W.H., Pan S.H., Sun B., World J. Induction of apoptosis by artemisinin relieving the severity of inflammation in caerulein-induced acute pancreatitis. Gastroenterol 2007, 13(42):5612-5617.